NCCN Academy
NCCN Academy for Excellence & Leadership in Oncology™: School of Pharmaceutical & Biotech Business
Thursday, October 28, 2021 | 3:00 – 6:00 PM EDT | Virtual Program
Overview
During this interactive online program, pharmaceutical and biotechnology professionals are given the rare opportunity to view the oncology space, its future and its current operational issues from the provider, advocacy, and payer perspectives. Through this pharmaceutical and biotech training program, participants will improve their working knowledge of key business, policy, coverage, reimbursement, informational, and operational issues in oncology while gathering valuable insights into developing effective strategies for navigating the cancer care ecosystem. Pharmaceutical and biotech professionals will learn from key stakeholders what they view to be the most pressing issues in oncology today and how to apply this knowledge to create mutually-successful working relationships.
Curriculum
- Welcome and Introductions
- Module I: Meet the NCCN Guidelines Panel Experts
- Module II: Diversity, Equity & Inclusion – Now What? A Follow Up from the Cancer Equity Initiative
Please check back often for additional updates regarding this program. If you have any questions, please contact Erin Green, Business Development Specialist, US Business Development.
Intended Audience
Professionals from advocacy, marketing, medical affairs, clinical research, policy and government affairs, and other business areas will better be able to serve their customers with improved knowledge of real-world oncology issues after completion of this program.
Past Academy Programs
Approximately 97 percent of recent NCCN Academy attendees say they would attend an NCCN Academy program again or recommend that colleagues attend.
The last Virtual Academy Program was held on March 25, 2021.
Customize your own NCCN Academy curriculum.
NCCN offers the unique opportunity to customize an NCCN Academy curriculum that best aligns with your organization's particular needs and interests.